Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: A promising approach

Hematological Oncology

Volumn 24, Issue 2, 2006, Pages 47-55

  Vose, Julie M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Idiotype; Immunotherapy; Lymphoma; Vaccine

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IMMUNOMODULATING AGENT; INHIBITOR OF DIFFERENTIATION PROTEIN; KEYHOLE LIMPET HEMOCYANIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; CLINICAL TRIAL; FEVER; FOLLICULAR LYMPHOMA; HUMAN; HYPOTENSION; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INJECTION SITE REACTION; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIGOR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY;

EID: 33745790265     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.770     Document Type: Review

References (64)

1. Timmerman J, Levy R, Vose J, et al. A phase 2 trial to evaluate the rate of immune response using recombinant idiotype for treatment of follicular non-Hodgkin's lymphoma. J Immunol 2001; 24: 514.
2. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotypepulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517-1526.
3. Koc O, Redfern C, Wierknik P. Id/KLH vaccine (FavId) following treatment with rituximab: an analysis of response rate improvement (RRI) and time to progression (TTP) in follicular lymphoma. Blood 2004; 104: (abstr 587).
4. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
5. McLaughlin P. Progress and promise in the treatment of indolent lymphomas. Oncologist 2002; 7: 217-225.
6. Ganti AK, Bociek RG, Bierman PJ, et al. Follicular lymphoma: expanding therapeutic options. Oncology (Williston Park) 2005; 19: 213-228; discussion 228; 233-216: 239.
7. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75-88.
8. Anderson T, Chabner BA, Young RC, et al. Malignant lymphoma, 1: the histology and staging of 473 patients at the National Cancer Institute. Cancer 1982; 50: 2699-2707.
9. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma?: results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282-1290.
10. Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003; 57: 1382-1391.
11. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-522.
12. Ezdinli EZ, Andersen JR, Melvin F, et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 1985; 3: 769-775.
13. Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J 1978; 1: 533-537.
14. Kimby E, Bjorkholm M, Gahrton G, et al. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; 5(Suppl. 2): 67-71.
15. McLaughlin P, Cabanillas F, Hagemeister FB, et al. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 1993; 4: 205-211.
16. Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003; 21: 5-15.
17. Kennedy BJ, Bloomfield CD, Kiang DT, et al. Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer 1978; 41: 23-28.
18. Hiddemann W, Dreyling M, Forstpointner R, et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma-results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003; 102: (abstr 352).
19. Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomized, open-label phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma. Blood 2003; 102: (abstr 87).
20. Winter JN, Gascoyne RD, Van Besien K. Low-grade lymphoma. Hematology (Am Soc Hematol Educ Program) 2004; 104: 203-220.
21. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-1423.
22. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
23. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
24. Timmerman JM. Immunotherapy for lymphomas. Int J Hematol 2003; 77: 444-455.
25. Krikorian JG, Portlock CS, Cooney P, et al. Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer 1980; 46: 2093-2099.
26. Anonymous. Biologic response modifiers: a report. Natl Cancer Inst Monogr 1983; 63: 57-59.
27. Fefer A. Interleukin-2: clinical applications-hematologic malignancies. In Principles and Practice of the Biologic Therapy of Cancer, Rosenberg SA (ed.). Lippincott Williams & Wilkins: Philadelphia, PA, 2000; 83-92.
28. Tedder TF, Tuscano J, Sato S, et al. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 15: 481-504.
29. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450-454.
30. Domagala A, Kurpisz M. CD52 antigen-a review. Med Sci Monit 2001; 7: 325-331.
31. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003; 9: 3991S-3994S.
32. Uppenkamp M, Engert A, Diehl V, et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 2002; 81: 26-32.
33. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphomalong-term results of a clinical trial. Blood 1997; 89: 3129-3135.
34. Neelapu S, Gause BL, Kikcevich D, et al. Vaccine therapy of follicular lymphoma in first remission: long-term follow-up of phase II results and high rate of chemotherapy-induced complete remissions in a controlled, randomized phase III trial. Blood 2003; 102: (abstr 4953).
35. Stevenson GT, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 1975; 254: 714-716.
36. Meeker TC, Lowder J, Maloney DG, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985; 65: 1349-1363.
37. Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 1985; 312: 1658-1665.
38. Lynch RG, Graff RJ, Sirisinha S, et al. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 1972; 69: 1540-1544.
39. Campbell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987; 139: 2825-2833.
40. Kaminski MS, Kitamura K, Maloney DG, et al. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 1987; 138: 1289-1296.
41. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209-1215.
42. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
43. Kwak LW, Young HA, Pennington RW, et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1996; 93: 10972-10977.
44. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171-1177.
45. Hawkins RE, Zhu D, Ovecka M, et al. Idiotypic vaccination against human B-cell lymphoma: rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 1994; 83: 3279-3288.
46. Timmerman JM. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma. Adv Pharmacol 2004; 51: 271-293.
47. Timmerman J, Levy R, Czerwinski D, et al. A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccines in untreated follicular non-Hodgkin's lymphoma in the 'watch-and-wait' period. Proc Am Soc Clin Oncol 2002; 21:4a (abstr 13).
48. Genitope Web site. Genitope Protocol 2002-2009. Available at: http://www.genitope.com/tr2009.html. Accessed July 7, 2005.
49. Leonard J, Vose J, Timmerman J, et al. Recombinant idiotype-KLH vaccination (MyVax) following CHOP chemotherapy in mantel cell lymphoma. Blood 2003; 102: (abstr 357).
50. Genitope Web site. Genitope Annual Report. Available at http:// library.corporate-ir.net/library/14/142/142124/items/149418/ GTOP_AnnualReport.pdf. Accessed June 7, 2005.
51. Neelapu SS, Baskar S, Gause BL, et al. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin Cancer Res 2004; 10: 8309-8317.
52. Genitope Web site. Genitope Protocol 2000-03. Available at: http://www.genitope.com/tr2003.html. Accessed July 7, 2005.
53. Hurvitz SA, Timmerman JM. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther 2005; 5: 841-852.
54. Weng WK, Czerwinski D, Timmerman J, et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: 4717-4724.
55. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
56. Timmerman J, Vose J, Kunkel L, et al. A phase 2 study demonstrating recombinant idiotype vaccine elicits specific antididiotype immune responses in aggressive non-Hodgkin's lymphoma. Blood 2001; 98: 341a (abstr).
57. Eisenbeis CF, Caligiuri MA, Byrd JC. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clin Cancer Res 2003; 9: 5810-5812.
58. Vose J, Bierman P, Hollingsworth M, et al. A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccine with abbreviated course of granulocyte-macrophage colony-stimulating factor adjuvant in follicular non-Hodgkin's lymphoma. Blood 2002; 100: 361a (abstr 1397).
59. Borrello IM, Sotomayor EM. Cancer vaccines for hematologic malignancies. Cancer Control 2002; 9: 138-151.
60. Briones J, Timmerman JM, Panicalli DL, et al. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst 2003; 95: 548-555.
61. Gatza E, Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 2002; 169: 5227-5235.
62. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
63. Haasz R, Robinson E. Lymphocyte reactivity in healthy subjects and cancer patients. Acta Haematol 1977; 57: 331-338.
64. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10: 801-805.